Blockchain Registration Transaction Record

Tonix Pharmaceuticals Uplists to Nasdaq Global Select Market in 2026

Tonix Pharmaceuticals (TNXP) uplists to Nasdaq Global Select Market in 2026, boosting visibility. The biotech firm focuses on CNS and immunology treatments, including a new fibromyalgia drug.

This uplisting matters because it signals Tonix Pharmaceuticals' maturation as a biotechnology company, potentially attracting more institutional investors and increasing stock liquidity, which can benefit shareholders through enhanced valuation and stability. For patients, Tonix's focus on CNS and immunology treatments—like its new fibromyalgia drug TONMYA and pipeline candidates for conditions such as major depressive disorder and Lyme disease—highlights ongoing innovation in areas with limited therapeutic options, offering hope for improved health outcomes. In the broader market, such moves by biotech firms can drive sector confidence, encouraging investment in research that addresses critical medical needs.